Labisia pumila standardized extract ( SKF7 ®) reduces percentage of waist circumference and waist‐to‐height ratio in individuals with obesity
Authors' conclusion
SKF7® is potentially a novel therapeutic treatment for obesity, reflected by reductions in BW, BMI, WC and WHtR. The use of SKF7® suggests a dose-dependent reduction in abdominal obesity, exemplified by a decline in WC and WHtR.
Study context
- Population
- Individuals with obesity, January 2020–April 2021
- Participants
- 133 individuals
- Comparison
- L. pumila standardized extract vs placebo
Methodological detailsdose-ranging, double-blind, multicentre, placebo-controlled, phase 2
- Dose-ranging
- Double-blind
- Multicentre
- Placebo-controlled
- Phase 2
Primary result
As reported in the abstract
Percentage of change in BW, BMI, WC and WHtR
Each group vs placeboEstimate (CI)P value
SKF7® 750 mg
average treatment effect, % change in BW (mean) −2.915(−4.546 to −1.285)
P < 0.01SKF7® 750 mg
average treatment effect, % change in BMI −2.921(−4.551 to −1.291)
P < 0.01SKF7® 750 mg
average treatment effect, % change in WC (mean) −2.187(−3.784 to −0.589)
P < 0.01SKF7® 750 mg
average treatment effect, % change in WHtR (mean) −2.294(−3.908 to −0.681)
P < 0.01Further findings
Dose–response and effect size
- Effect size (f2), waist circumference (WC)
- 0.11
- Effect size (f2), waist-to-height ratio (WHtR)
- 0.13
- Incremental reduction in WC and WHtR consistent with gradual increase in total daily SKF7® from 375 to 750 mg
- WC and WHtR had higher effect size than body weight (BW) and body mass index (BMI)
Original publication
Labisia pumila standardized extract ( SKF7 ®) reduces percentage of waist circumference and waist‐to‐height ratio in individuals with obesity. Diabetes Obes Metab. Published 8 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →